Aura Biosciences, INC Schedule 13G passive stakes

Long Focus Capital Management, LLC and John Helmers report beneficial ownership of 4.9% of Aura Biosciences, Inc. common stock as of June 30, 2026.

Adage Capital Management, L.P. has reported beneficial ownership of 8.44% of Aura Biosciences, Inc. common stock, including shares issuable upon warrant exercise.

TCG Crossover and Chen Yu have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aura Biosciences, Inc.

Frazier Life Sciences entities filed an amended Schedule 13G, disclosing their beneficial ownership in Aura Biosciences, Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Aura Biosciences Inc., holding 3,336,027 shares of common stock.

Frazier Life Sciences funds and affiliates have filed an amended Schedule 13G, detailing their beneficial ownership in Aura Biosciences, Inc. common stock.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen disclose increased beneficial ownership in Aura Biosciences, Inc., reaching up to 7.6% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a reduction in its beneficial ownership stake in Aura Biosciences Inc. to 4.9% of common stock.

Frazier Life Sciences and its affiliated funds have filed a Schedule 13G, revealing a collective beneficial ownership of 6,315,678 shares, representing 9.9% of Aura Biosciences, Inc.'s common stock.

Long Focus Capital Management, LLC and John Helmers have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 6.6% of Aura Biosciences, Inc.'s Common Stock as of March 31, 2025.

Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have filed an amended Schedule 13G indicating they no longer beneficially own any shares of Aura Biosciences, Inc. common stock.

Eventide Asset Management, LLC and its principals, Finny Kuruvilla and Robin C. John, have filed an amendment to their Schedule 13G, reporting zero beneficial ownership in Aura Biosciences, Inc.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have disclosed beneficial ownership exceeding 5% in Aura Biosciences, Inc. common stock.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported a beneficial ownership of 8.17% in Aura Biosciences, Inc.'s common stock as of December 31, 2024.

Long Focus Capital Management, LLC and affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 5.0% in Aura Biosciences, Inc. as of December 24, 2024.

A group of entities and individuals, including Long Focus Capital Management, LLC and John Helmers, have disclosed a passive ownership stake in Aura Biosciences, Inc., with John Helmers beneficially owning 5.7% of the common stock.